Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
Ramakrishnan S, Granger V, Rak M, Hu Q, Attwood K, Aquila L, Krishnan N, Osiecki R, Azabdaftari G, Guru K, Chatta G, Gueron G, McNally L, Ohm J, Wang J, Woloszynska A. Ramakrishnan S, et al. Among authors: granger v. Cell Death Differ. 2019 Oct;26(10):2100-2114. doi: 10.1038/s41418-019-0278-9. Epub 2019 Jan 28. Cell Death Differ. 2019. PMID: 30692641 Free PMC article.
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer.
Ramakrishnan S, Hu Q, Krishnan N, Wang D, Smit E, Granger V, Rak M, Attwood K, Johnson C, Morrison C, Pili R, Chatta G, Guru K, Gueron G, McNally L, Wang J, Woloszynska-Read A. Ramakrishnan S, et al. Among authors: granger v. Cell Death Dis. 2017 Dec 14;8(12):3217. doi: 10.1038/s41419-017-0024-5. Cell Death Dis. 2017. PMID: 29242529 Free PMC article.
Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial.
Adam R, Badrudin D, Chiche L, Bucur P, Scatton O, Granger V, Ducreux M, Cillo U, Cauchy F, Lesurtel M, Mabrut JY, Verslype C, Coubeau L, Hardwigsen J, Boleslawski E, Muscari F, Jeddou H, Pezet D, Heyd B, Lucidi V, Geboes K, Lerut J, Majno P, Grimaldi L, Boukhedouni N, Piedvache C, Gelli M, Levi F, Lewin M. Adam R, et al. Among authors: granger v. EClinicalMedicine. 2024 Apr 27;72:102608. doi: 10.1016/j.eclinm.2024.102608. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38721015 Free PMC article.
Circulating microbiome analysis in patients with perioperative anaphylaxis.
de Chaisemartin L, Ciocan D, Gouel-Chéron A, Granger V, Longrois D, Montravers P, Cassard AM, Chollet-Martin S. de Chaisemartin L, et al. Among authors: granger v. Front Immunol. 2024 Jan 11;14:1241851. doi: 10.3389/fimmu.2023.1241851. eCollection 2023. Front Immunol. 2024. PMID: 38274796 Free PMC article.
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
Taïeb J, Bouche O, André T, Le Malicot K, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, Corbinais S, Perrier H, Buecher B, Di Fiore F, Gallois C, Emile JF, Lepage C, Elhajbi F, Tougeron D; SAMCO-PRODIGE 54 Investigators. Taïeb J, et al. JAMA Oncol. 2023 Oct 1;9(10):1356-1363. doi: 10.1001/jamaoncol.2023.2761. JAMA Oncol. 2023. PMID: 37535388 Free PMC article.
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C. Walter T, et al. Among authors: granger v. Lancet Oncol. 2023 Mar;24(3):297-306. doi: 10.1016/S1470-2045(23)00001-3. Epub 2023 Feb 2. Lancet Oncol. 2023. PMID: 36739879 Clinical Trial.
Differential activation of human neutrophils by SARS-CoV-2 variants of concern.
Lebourgeois S, David A, Chenane HR, Granger V, Menidjel R, Fidouh N, Noël B, Delelis O, Richetta C, Charpentier C, Chollet-Martin S, Descamps D, Visseaux B, de Chaisemartin L. Lebourgeois S, et al. Among authors: granger v. Front Immunol. 2022 Oct 27;13:1010140. doi: 10.3389/fimmu.2022.1010140. eCollection 2022. Front Immunol. 2022. PMID: 36389717 Free PMC article.
Immediate hypersensitivity to COVID-19 vaccines: Focus on biological diagnosis.
Nicaise-Roland P, Granger V, Soria A, Barbaud A, Pallardy M, Chollet-Martin S, de Chaisemartin L. Nicaise-Roland P, et al. Among authors: granger v. Front Allergy. 2022 Sep 30;3:1007602. doi: 10.3389/falgy.2022.1007602. eCollection 2022. Front Allergy. 2022. PMID: 36249342 Free PMC article. Review.
59 results